Deciphering patient-specific PD-1/PD-L1 expression and polymorphism could be of critical importance in T1D, since it was observed that T1D patients responding to anti-CD3 teplizumab therapy exhibit an exhausted T-cell phenotype characterized by PD-1 expression [62,63]. Here, PDCD1 is linked to type 1 diabetes mellitus.